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Abstract 
The purpose of this study was to investigate whether the overall treatment time and completion rates of chemo-
therapy were predictive factors for the survival rates in patients with squamous cell carcinoma of the head and neck 
(SCCHN) who were treated with concurrent chemoradiotherapy (CCRT) using hyperfractionated radiotherapy (RT) 
and daily carboplatin. The number of intermission days of RT were as follows; 0 (n = 37), 1–5 (n = 8), 6–10 (n = 12) 
and ≥11 (n = 12), and the days of RT without carboplatin; 0 (n = 27), 1–5 (n = 13), 6–10 (n = 13) and ≥7 (n = 16). The 
overall treatment time (≤48 vs ≥49 days) was a significant prognostic factor for the local control, disease-free survival 
and overall survival rates. The completion rate of chemotherapy, as the number of days of RT without carboplatin, was 
not a significant factor affecting any of the survival rates. In discussion, the strengths of the present study contain that 
all the patients were treated with 72 Gy delivered as 1.2 Gy twice daily, and received concurrent chemotherapy com-
prising daily carboplatin as a radio-sensitizer. Based on the results, the completion rate of chemotherapy may have a 
lower impact on the local control rate in comparison with the overall treatment time. We believe that when a treat-
ment interruption is needed because of the acute toxicities, hyperfractionated RT should be resumed as soon as pos-
sible independently while continuing the break of daily carboplatin. The overall treatment time influenced the clinical 
outcomes in SCCHN patients treated with hyperfractionated CCRT using carboplatin, while the impact of the com-
pletion rates of daily carboplatin was limited. Sixty-nine consecutive patients with SCCHN were initially treated with 
definitive CCRT and were retrospectively analyzed. All 69 patients were treated with CCRT using hyperfractionated RT 
of 72 Gy in 60 fractions and daily carboplatin (25 mg/m2). The patients treated with other chemotherapeutic regimens 
or induction chemotherapy were excluded. On the intermission days of the RT, carboplatin was not prescribed. After 
the intermission, CCRT using RT plus daily carboplatin or RT alone was resumed.
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Background
The prolongation of the overall treatment time of radi-
otherapy (RT) results in poorer clinical outcomes in 
patients with squamous cell carcinoma of the head and 
neck (SCCHN) (Duncan et  al. 1996). Hyperfractionated 
RT has been used for head and neck cancers, especially 
for advanced cases, because it reduces the opportunity 
for the proliferation of tumor cells and increases the 
efficiency of tumor control without increasing late tox-
icity. Phase III randomized trials have demonstrated a 
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significant improvement in the local control of head and 
neck cancers treated with twice-daily fractionation over 
once daily fractions (Horiot et  al. 1992). Chemoradio-
therapy has also been studied intensively in patients with 
SCCHN, (Marcial et al. 1990; Munro 1995). Concurrent 
chemoradiotherapy (CCRT) is attractive because chem-
otherapeutic agents may act as radiosensitizers, and the 
overall treatment time is not prolonged (Munro 1995). 
In the meta-analyses of head and neck cancers, the sur-
vival benefit of chemotherapy given synchronously with 
RT has been demonstrated (Munro 1995). In this context, 
concurrent chemoradiotherapy (CCRT) and hyperfrac-
tionated RT have been used for SCCHN, and the efficacy 
of CCRT using hyperfractionated RT was confirmed in a 
meta-analysis (Budach et al. 2006).
There have been only a few reports that have investi-
gated whether the overall treatment time or completion 
rate of concurrent chemotherapy is a prognostic factor 
in SCCHN patients treated with CCRT using conven-
tional fractionated RT (Pignon et  al. 2000; Langendijk 
et al. 2004). However, to the best of our knowledge, there 
have been no reports that have evaluated the prognostic 
impact of the overall treatment time or completion rate 
of concurrent chemotherapy in patients treated with 
CCRT using hyperfractionated RT. The purpose of this 
study was therefore to investigate the prognostic impact 
of the overall treatment time and completion rates of 
chemotherapy in patients with SCCHN who were treated 
with CCRT using hyperfractionated RT.
Results and discussion
The follow-up ranged from 3 to 120  months (median, 
46  months). Table  1 shows the number of intermis-
sion days of RT and days of RT without carboplatin. The 
3-year LC, DFS, DMFS and OS rates in all 69 patients 
were 66, 62, 90 and 75  % respectively. Local recurrence 
and distant metastasis developed in 24 (39 %) and seven 
(10 %) patients, respectively.
Table 2 summarizes the results of the univariate analy-
ses by the Kaplan–Meier approach with log-rank testing 
to evaluate the impact of certain factors on the survival 
rates. The number of overall treatment days was a sig-
nificant prognostic factor for the LC, DFS and OS rates 
(Figs. 1, 2). The completion rate of chemotherapy, as the 
number of days of RT without carboplatin, was not a sig-
nificant factor associated with any of the survival rates 
(Fig. 3). The clinical stage was a significant factor associ-
ated with the LC, DFS DMFS and OS. The T stage was 
also a significant predictor of the LC, DFS and OS.
In discussion, the present study is the first study to 
evaluate the overall treatment time of RT and the com-
pletion rates of chemotherapy for SCCHN patients 
treated with CCRT using hyperfractionated RT. The 
strengths of the present study include that all the patients 
were initially treated with 72 Gy delivered as 1.2 Gy twice 
daily, and received concurrent chemotherapy comprising 
daily carboplatin as a radio-sensitizer for the hyperfrac-
tionated RT (Chitapanarux et  al. 2007). In addition, the 
patients who received neoadjuvant chemotherapy, fol-
lowed by radiotherapy, were not included. Therefore, the 
effects of the overall treatment time and completion rates 
of daily carboplatin on the clinical outcomes could be 
evaluated with less bias. Our results confirmed that the 
overall treatment time was a significant factor predicting 
the LC, DFS and OS rates, while the completion rate of 
daily carboplatin was not.
In many of the previous studies of the clinical outcomes 
of RT alone, an interruption of RT was found to be a sig-
nificant predictor of the local control (Bese et al. 2007). 
RT alone with a hyperfractionated schedule also showed 
a significant improvement in the LC and DFS in patients 
treated with shorter overall treatment times (Leborgne 
et al. 2001). However, as mentioned in the Introduction, 
there have been limited clinical reports about treatment 
interruption in SCCHN patients treated with CCRT 
(McCloskey et  al. 2009; Gupta et  al. 2009). McCloskey 
et  al. reported that RT treatment interruption greater 
than 1 week was a significant predictor of worse LC after 
definitive CCRT using cisplatin (most common regimen 
100 mg/m2 on days 1, 22 and 43) and conventional frac-
tionated RT (McCloskey et  al. 2009). Gupta et  al. dem-
onstrated that the total cycles (≥6 cycles) of concurrent 
weekly cisplatin (30 mg/m2), as well as a shorter overall 
treatment time, was a significant prognostic factors for 
a better LC and DFS (Gupta et al. 2009). In the current 
study of CCRT using hyperfractionated RT and daily 
carboplatin, although the rate of completion of chemo-
therapy was not a prognostic factor, the overall treat-
ment time was a significant predictor. We supposed that 
the completion rate of chemotherapy may have a lower 
impact on the LC rate in comparison with the overall 
treatment time, because the daily low-dose regimen was 
prescribed mainly as a radio-sensitizer, and the antitu-
mor effects of hyperfractionated RT may strongly depend 
on the overall treatment time (Leborgne et al. 2001).
Table 1 The intermission of RT and days of RT without car-
boplatin
Days Intermission days  
of RT n (%)
Days of RT without  
carboplatin n (%)
0 37 (54) 27 (39)
1–5 8 (12) 13 (19)
6–10 12 (7) 13 (19)
11–20 11 (16) 13 (19)
21– 1 (1) 3 (4)
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A prolonged overall treatment time is a well-known 
factor that has a negative impact on the outcome of 
SCCHN due to tumor cell repopulation (Hoffstetter 
et  al. 1997; Tarnawski et  al. 2002; Suwinski et  al. 2003). 
Nishimura et al. reported that an overall treatment time 
longer than 49  days was significantly associated with a 
poor local control rate in patients with T1 or T2 glot-
tic carcinoma; a 1-week interruption of RT significantly 
Table 2 The results of the univariate analyses of factors predicting the survival rates
n Local control Disease-free survival Distant metastasis-free 
survival
Overall survival
3-year (%) p 3-year (%) p 3-year (%) p 3-year (%) p
Age (years) 0.41 0.44 0.81 0.82
 <65 33 72 67 87 79
 ≥65 36 62 59 91 70
PS 0.73 0.63 0.83 0.34
 0–1 59 68 64 87 77
 2–3 10 64 58 100 61
Clinical stage 0.007 0.0009 0.01 <0.0001
 I–II 35 84 84 100
 III–IV 34 50 39 49
Tumor stage <0.0001 <0.0001 0.17 <0.0001
 T1–2 55 79 74 80 87
 T3–4 14 23 17 90 34
N stage 0.05 0.0091 0.01 0.0012
 N0 38 77 77 97 94
 N1–3 31 54 43 76 52
Overall treatment (days) 0.039 0.015 0.11 0.02
 ≤48 45 78 74 91 84
 ≥49 24 48 41 85 56
Days of RT without carboplatin 0.69 0.61 0.82 0.21
 ≤5 40 68 64 83 80
 ≥6 29 64 41 95 67
Hemoglobin at the start of RT (g/dl) 0.30 0.22 0.66 0.02
 <12 18 51 44 83 57
 ≥12 51 71 68 92 82
Fig. 1 The overall treatment period (≤48 days) was a significant 
predictor of the local control rate (p = 0.039)
Fig. 2 The overall treatment period (≤48 days) was a significant 
predictor of the overall survival rate (p = 0.024)
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reduced the 5-year local control probability of T1 glot-
tic tumors from 89 to 74  % (Nishimura et  al. 1996). 
Kawashima et al. also indicated that the patients who had 
received 70  Gy/≤49  days for accelerated fractionation 
RT achieved a better local control rate than those who 
had received other, more conservative total dose/overall 
treatment time with statistical significance in patients 
with T2 or worse hypopharyngeal cancer (Kawashima 
et al. 2007). According to these clinical results, we chose 
≤49 and ≥49  days as the difference in treatment time, 
and recommended that patients receive radiation ther-
apy for a maximum of 48 days and no longer, because we 
confirmed that the overall treatment time (≤49 days) was 
a significant prognostic factor for the survival rates in the 
current study.
Hyperfractionated RT has resulted in increased severe 
acute complications requiring intensive nutritional sup-
port for the completion of treatment in some patients. 
Wang et  al. suggested that a prolongation of the treat-
ment gap for more than 14  days adversely affected the 
local control in patients with locally advanced head and 
neck cancer treated with accelerated hyperfraction-
ated radiation therapy, and the midcourse treatment gap 
should be kept as short as possible (Wang et al. 1996). In 
a Phase III trial of hyperfractionated RT with or without 
concurrent chemotherapy for locally advanced head and 
neck cancer, combined treatment for advanced head and 
neck cancer was more efficacious than hyperfractionated 
RT alone (Brizel et al. 1998). This trial included planned 
treatment breaks to avoid the withdrawal of the recruited 
subjects due to acute toxicity; eventually, the treatment 
time of RT in the hyperfractionated RT arm averaged 
42  days, while that in the hyperfractionated RT plus 
concurrent chemotherapy arm averaged 47  days (Bri-
zel et al. 1998). However, the long-term follow-up in the 
Phase III Radiation Therapy Oncology Group (RTOG) 
0129 trial indicated no difference in the overall survival 
or late toxicity with the use of accelerated-hyperfraction-
ated vs standard RT plus cisplatin in patients with locally 
advanced head and neck cancer (Nguyen-Tan et al. 2014). 
Based on the results of the present study of CCRT using 
hyperfractionated RT and daily carboplatin, we believe 
that when a treatment interruption is needed because 
of the acute toxicities, hyperfractionated RT should be 
resumed as soon as possible independently while contin-
uing the break of daily carboplatin.
Regarding the limitations associated with this study, 
it was a retrospective case series, so the possibility that 
there was some selection bias with regard to the prog-
nostic factors could not be ruled out, although all of the 
patients received definitive CCRT using hyperfraction-
ated RT of 70  Gy in 60 fractions and daily carboplatin, 
and were initially treated with non-surgical management. 
The treatment regimen of CCRT using hyperfraction-
ated RT and daily carboplatin differed from the standard 
therapy, such as CCRT using conventional fractionation 
and cisplatin. However, a Phase III randomized trial of 
CRT using cisplatin vs. carboplatin for head and neck 
cancer demonstrated that there was no difference in the 
survival rates between cisplatin and carboplatin, and the 
completion rates of carboplatin was higher than that of 
cisplatin (Chitapanarux et al. 2007). In addition, a signifi-
cant improvement in the local control of head and neck 
cancers treated with twice-daily fractionation over once 
daily fractions in Phase III randomized trials for RT mon-
otherapy for head and neck cancer was observed (Horiot 
et al. 1992). Therefore, we chose this regimen presuming 
an improvement in the treatment results in patients with 
SCCHN. A formal prospective trial is necessary to deter-
mine the prognostic impact of the overall treatment time 
and completion rate of chemotherapy in patients treated 
with CCRT using hyperfractionated RT.
Conclusions
In conclusion, this study demonstrated that the longer 
overall treatment time may have a negative impact on 
the clinical outcomes in SCCHN patients treated with 
concurrent CCRT using hyperfractionated RT and daily 
carboplatin, while the completion rates of daily carbopl-
atin may not affect the clinical outcomes. When the acute 
toxicities that need the treatment interruption occur, it is 
important to consider the early resume of hyperfraction-
ated RT without restart of the daily carboplatin.
Methods
From June 1999 to January 2010, 608 consecutive 
patients with primary head and neck cancer were pro-
spectively recorded in the database for RT at the authors’ 
institution. The following requirements had to be met for 
Fig. 3 The rate of completion of chemotherapy, as the number of 
days of RT without carboplatin, was not a significant predictor of the 
local control rate
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patients to be included in this retrospective study: a path-
ologically confirmed SCCHN, treated with concurrent 
chemoradiotherapy (CCRT) using hyperfractionated RT 
of 72 Gy in 60 fractions and daily carboplatin (25 mg/m2), 
without distant metastatic disease. The following patients 
were excluded: those who had been treated with neoad-
juvant chemotherapy, had received transoral debulking 
microsurgery and those who had postoperative disease. 
Sixty-nine patients were selected from the database and 
were retrospectively analyzed. Written informed consent 
for treatment was obtained from all patients. The study 
was approved by the Institutional Review Board of the 
authors’ institution.
The characteristics of the patients are listed in Table 3. 
The performance status and tumor invasion were evalu-
ated at the start of our treatment. Staging was achieved 
by clinical examination, CT and endoscopic examina-
tion, and in some cases, magnetic resonance imaging 
(MRI) and 18-Fluoro-deoxyglucose positron emission 
tomography (FDG-PET). All 69 patients were treated 
with two daily fractions of radiation of 1.2 Gy (total dose, 
72 Gy), with a 6-h interval between fractions. Computed 
tomography-assisted three-dimensional treatment plan-
ning (Xio or FOCUS; CMS Japan, Tokyo, Japan) was 
used to determine the radiation fields. Uninvolved nodal 
areas of the neck were treated with 43.2  Gy/36  Fr. The 
primary tumor and gross nodal disease were treated 
with 72 Gy/60 Fr. Prophylactic neck irradiation for unin-
volved nodal areas was not performed in 14 patients with 
T2N0M0 glottic cancer of the larynx.
The detailed irradiation and concurrent chemotherapy 
schedules are shown in Fig. 4. Carboplatin was planned 
to be administered as an intravenous bolus immediately 
before the first daily fraction at a dose of 25  mg/m2 on 
every treatment day. On the intermission days of the 
hyperfractionated RT, carboplatin was not prescribed. 
After the intermission, CCRT using hyperfractionated 
RT plus daily carboplatin or hyperfractionated RT alone 
was resumed.
In all patients, complete head and neck examinations, 
including flexible laryngoscopy, were performed after the 
completion of CCRT and every 1–3 months for the first 
year, every 2–3  months for the second and third years 
and every 2–6 months for the fourth and fifth years after 
the CCRT. CT scans were performed every 3–6 months 
at the discretion of the clinician, and in some patients, 
fluorodeoxyglucose positron emission tomography/com-
puted tomography (FDG-PET/CT) or magnetic reso-
nance imaging (MRI) was additionally used.
The local control (LC), defined as failure to have a 
recurrence within the radiation field, the disease-free 
survival (DFS), distant metastasis-free survival (DMFS) 
and overall survival (OS) rates were calculated from the 
start of RT using the Kaplan–Meier method. The statis-
tical significance of the differences between the actuarial 
curves was assessed using the log-rank test. To identify 
prognostic factors for the survival rates, univariate anal-
yses were performed using the age, performance status, 
clinical stage, T stage, N stage, overall treatment days, 
Table 3 The patient characteristics




 Median (range) 69 (40–85)
Gender
 Male 60 (87)
 Female 9 (13)
Performance status
 0 12 (17)
 1 46 (67)
 2 10 (15)
 3 1 (1)
Tumor type, TNMa
 Nasopharyngeal ca. 5 (7)
  T1N2M0 1
  T1N3M0 1
  T2N1M0 3
 Oropharyngeal ca. 15 (22)
  T1N0M0 1
  T1N2M0 4
  T2N0M0 1
  T2N1M0 2
  T2N2M0 1
  T3N1M0 1
  T4N1M0 1
  T4N2M0 1
  T4N3M0 3
 Hypopharyngeal ca. 22 (32)
  T1N0M0 2
  T1N2M0 1
  T2N0M0 8
  T2N1M0 1
  T2N2M0 4
  T3N2M0 2
  T4N0M0 2
  T4N2M0 2
 Laryngeal ca. 27 (39)
  T2N0M0 22
  T2N1M0 1
  T2N2M0 2
  T3N0M0 1
  T3N2M0 1
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days of RT without carboplatin and the hemoglobin 
level at the start of RT. Multivariate analysis was not per-
formed because of the small number of patients.
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